IgA Antibodies Against the Epstein-Barr Nuclear Antigen1 as a Valuable Biomarker for the Diagnosis of Nasopharyngeal Carcinoma in Tunisian Patients
IgA Antibodies Against the Epstein-Barr Nuclear Antigen1 as a Valuable Biomarker for the Diagnosis of Nasopharyngeal Carcinoma in Tunisian Patients
复制标题
DOI：
10.1002/jmv.21532
复制
发表时间：
2009-08-01
影响因子：
12.7
通讯作者：
Hammami, Adnane
中科院分区：
文献类型：
--
作者：
Ayadi, Wajdi;Karray-Hakim, Hela;Hammami, Adnane
eb病毒（EBV）的血清学检测已被用作鼻咽癌的诊断预测指标多年。以往的研究表明，传统的免疫荧光检测诊断价值有限，特别是在北非地区的年轻患者中。为了寻找更可靠的用于鼻咽癌诊断的免疫球蛋白（Ig） G或IgA抗体标记物，使用EBV蛋白全谱进行了免疫印迹分析。收集了108例鼻咽癌患者的血清和3个对照组，其中18例为淋巴瘤患者，18例为其他自身免疫性疾病患者，55例为健康EBV携带者。我们观察到，IgA eb - barr核抗原1 （EBNA1）、IgA早期抗原(EA)-p138和IgG EA-p138抗体在年轻和老年鼻咽癌患者中都是最特异的抗ebv抗体，与三个对照组相比，阳性率更高。由于IgA EBNA1反应对鼻咽癌的检测灵敏度最高，我们利用细菌表达的GST-EBNA1蛋白建立了一种新的酶联免疫吸附试验（ELISA），该蛋白含有从C15异种移植细胞DNA EBV序列克隆的对苏氨酸EBNA1亚型。年轻和老年鼻咽癌患者的检出率分别为85.7%和94.9%，而健康EBV携带者、淋巴瘤患者和自身免疫性疾病患者的检出率分别为3.6%、11.1%和16.6%。因此，IgA EBNA1 ELISA可能有助于突尼斯鼻咽癌的早期诊断和大规模筛查，即使是年轻患者。中华医学杂志，2009,31(1):444 - 444。(C) 2009 Wiley-Liss, Inc。
Serological tests for Epstein-Barr virus (EBV) have been used for many years as diagnostic predictors of nasopharyngeal carcinoma. It has been shown previously that the conventional immunofluorescence assay has a limited diagnostic value, especially in young patients from North African area. In the search for more reliable immunoglobulin (Ig) G or IgA antibody markers for the diagnosis of nasopharyngeal carcinoma, immunoblot analysis was performed using a full spectrum of EBV proteins. Sera were collected from 108 patients with nasopharyngeal carcinoma and three control groups composed of 18 patients with lymphoma, 18 other patients with autoimmune diseases and 55 healthy EBV carriers. It was observed that the IgA Epstein-Barr nuclear antigen 1 (EBNA1), IgA early antigen (EA)-p138 and IgG EA-p138 antibodies represent the most specific anti-EBV responses in either young or older patients with nasopharyngeal carcinoma which yield higher positive rates compared to the three control groups. Since the IgA EBNA1 response showed the highest sensitivity value for the detection of nasopharyngeal carcinoma, a novel enzyme-linked immunosorbent assay (ELISA) was established using a GST-EBNA1 protein expressed in bacteria, containing the P-threonine EBNA1 subtype cloned from DNA EBV sequence of C15 xenograft cells. Detection rates were 85.7% and 94.9% in young and older patients with nasopharyngeal carcinoma respectively, while only 3.6%, 11.1%, and 16.6% in healthy EBV carriers, patients with lymphoma and patients with autoimmune diseases, respectively. Thus, IgA EBNA1 ELISA may be useful for early diagnosis and mass screening of nasopharyngeal carcinoma in Tunisia even in young patients. J. Med. Virol. 81:1412-1421, 2009. (C) 2009 Wiley-Liss, Inc.